Royalty Pharma Plc annual earnings per share (EPS) for fiscal TTM was $1.48, an increase of 7.2% from $1.38 in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| EPS (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (EPS) | $1.48 | $1.38 | $1.45 | $1.88 | $0.08 | $1.49 | $2.60 | $6.63 | $3.89 | $3.42 | $0.93 | $0.96 | $-0.09 | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EPS (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (EPS) | $0.53 | $0.38 | $0.52 | $0.05 | $0.41 | $0.35 | $0.92 | $0.17 |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More RPRX metrics: Revenue · Gross Profit · Operating Income · Net Income · EBITDA · Free Cash Flow · Shares Outstanding
All RPRX financial statements → Interactive RPRX charts →
About TickerBase · Data methodology & sources